Sponsored by

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma Histopathology Reporting Guide

Family/Last name

Given name(s)

Date of birth DD – MM – YYYY

Patient identifiers

Date of request DD – MM – YYYY

Accession/Laboratory number

Elements in **black text** are CORE. Elements in **grey text** are NON-CORE.

☐ indicates multi-select values ◯ indicates single select values

SCOPE OF THIS DATASET

CLINICAL INFORMATION (select all that apply)

- ◯ Information not provided
- ☐ Known gene predisposition (e.g., *BRCA1*, *BRCA2*, Lynch syndrome), *specify*
- ☐ Prior neoadjuvant therapy, *specify*
- ☐ Other, *specify*

SPECIMEN(S) SUBMITTED (select all that apply)

- ◯ Not specified
- ☐ Ovary
  - ☐ Left ☐ Right ◯ Laterality not specified
- ☐ Ovarian cystectomy
  - ☐ Left ☐ Right ◯ Laterality not specified
- ☐ Fallopian tube
  - ☐ Left ☐ Right ◯ Laterality not specified
- ☐ Uterus
- ☐ Cervix
- ☐ Omentum
- ☐ Peritoneal biopsies
- ☐ Peritoneal washings/peritoneal fluid
- ☐ Lymph nodes, *specify site(s)*
- ☐ Other, *specify*

SPECIMEN INTEGRITY (select all that apply)

(Required only if ovary(ies)/fallopian tube(s) are submitted)

Left ovary

- ☐ Ovarian capsule intact
- ☐ Ovarian capsule ruptured
  - ◯ Information not provided
  - ◯ Preoperatively
  - ◯ Intraoperatively
- ☐ Tumour on surface
- ☐ Fragmented specimen
- ☐ Other, *specify*

Right ovary

- ☐ Ovarian capsule intact
- ☐ Ovarian capsule ruptured
  - ◯ Information not provided
  - ◯ Preoperatively
  - ◯ Intraoperatively
- ☐ Tumour on surface
- ☐ Fragmented specimen
- ☐ Other, *specify*

Left fallopian tube

- ☐ Serosa intact
- ☐ Serosa ruptured
  - ◯ Information not provided
  - ◯ Preoperatively
  - ◯ Intraoperatively
- ☐ Tumour on serosal surface
- ☐ Fragmented specimen
- ☐ Other, *specify*

Right fallopian tube

- ☐ Serosa intact
- ☐ Serosa ruptured
  - ◯ Information not provided
  - ◯ Preoperatively
  - ◯ Intraoperatively
- ☐ Tumour on serosal surface
- ☐ Fragmented specimen
- ☐ Other, *specify*

TUMOUR SITE (select all that apply)

- ◯ No macroscopically visible tumour
- ◯ Indeterminate
- ☐ Ovary
  - ☐ Left ☐ Right ◯ Laterality not specified
- ☐ Fallopian tube
  - ☐ Left ☐ Right ◯ Laterality not specified
    - ☐ Fimbrial ☐ Fimbrial
    - ☐ Non-fimbrial ☐ Non-fimbrial
- ☐ Peritoneum
- ☐ Other, *specify*

TUMOUR DIMENSIONS

(If separate tumours specify dimensions for each site)

mm x mm x mm

MACROSCOPIC DESCRIPTION OF OMENTUM

(Required only if omentum submitted)

Omentum dimensions

mm x mm x mm

Omental involvement

- ◯ Not involved
- ◯ Involved

Maximum dimension of largest tumour deposit mm

Version 2.1 Published September 2021 ISBN: 978-1-922324-25-2

BLOCK IDENTIFICATION KEY

(List overleaf or separately with an indication of the nature and origin of all tissue blocks)

HISTOLOGICAL TUMOUR TYPE (select all that apply)

(Value list based on the World Health Organization Classification of Female Genital Tumours (2020))

- ☐ Serous borderline tumour
- ☐ Low grade serous carcinoma
- ☐ High grade serous carcinoma
- ☐ Mucinous borderline tumour
- ☐ Mucinous carcinoma
- ☐ Endometrioid borderline tumour
- ☐ Endometrioid carcinoma
- ☐ Clear cell borderline tumour
- ☐ Clear cell carcinoma
- ☐ Seromucinous borderline tumour
- ☐ Borderline Brenner tumour
- ☐ Malignant Brenner tumour
- ☐ Mesonephric-like adenocarcinoma
- ☐ Carcinoma, undifferentiated
- ☐ Dedifferentiated carcinoma
- ☐ Carcinosarcoma
- ☐ Mixed carcinoma
- ☐ Neuroendocrine neoplasm, *specify type*

  _____

- ☐ Other, *specify*

  _____

PATTERN OF INVASION

(Applicable for mucinous carcinomas only)

- ○ Expansile
- ○ Infiltrative/destructive

CARCINOSARCOMA COMPONENTS (select all that apply)

- ☐ Epithelial
  - Percentage _____ %
  - List components _____
- ☐ Sarcomatous
  - Percentage _____ %
  - Type ○ Homologous ○ Heterologous
  - List components _____

HISTOLOGICAL TUMOUR GRADE

Endometrioid carcinomas

- ○ GX: Cannot be assessed
- ○ G1: Well differentiated
- ○ G2: Moderately differentiated
- ○ G3: Poorly differentiated

Mucinous carcinomas

- ○ GX: Cannot be assessed
- ○ G1: Well differentiated
- ○ G2: Moderately differentiated
- ○ G3: Poorly differentiated

BORDERLINE TUMOUR - SPECIAL FEATURES

(Applicable only if borderline tumour is identified)

Micropapillary architecture for serous borderline tumour *(at least 5 mm in one dimension)*

- ○ Not identified
- ○ Present

Microinvasion *(upper limit 5 mm)*

- ○ Not identified
- ○ Present

Intraepithelial carcinoma for mucinous borderline tumour

- ○ Not identified
- ○ Present

Implants for serous and seromucinous borderline tumour (select all that apply)

- ☐ Non-invasive implants
  - ○ Not identified
  - ○ Present
    - ○ Epithelial
    - ○ Desmoplastic
    - Site(s) ☐ Pelvic ☐ Abdominal
- ☐ Invasive implants/Extra-ovarian low grade serous carcinoma
  - ○ Not identified
  - ○ Present
    - Site(s) ☐ Pelvic ☐ Abdominal
- ☐ Indeterminate
  - ○ Not identified
  - ○ Present
    - Site(s) ☐ Pelvic ☐ Abdominal

SEROUS TUBAL INTRAEPITHELIAL CARCINOMA (STIC)

(Required only if fallopian tube(s) are submitted)

Left fallopian tube	Right fallopian tube
○ Cannot be assessed	○ Cannot be assessed
○ Not identified	○ Not identified
○ Present (select all that apply)	○ Present (select all that apply)
☐ Fimbrial	☐ Fimbrial
☐ Non-fimbrial	☐ Non-fimbrial

Version 2.1 Published September 2021 ISBN: 978-1-922324-25-2

HISTOLOGICAL SITES OF TUMOUR INVOLVEMENT

Left ovary
- ◯ Not applicable
- ◯ Cannot be assessed
- ◯ Not involved
- ◯ Involved

Right ovary
- ◯ Not applicable
- ◯ Cannot be assessed
- ◯ Not involved
- ◯ Involved

Left fallopian tube
- ◯ Not applicable
- ◯ Cannot be assessed
- ◯ Not involved
- ◯ Involved

Right fallopian tube
- ◯ Not applicable
- ◯ Cannot be assessed
- ◯ Not involved
- ◯ Involved

Uterus
- ◯ Not applicable
- ◯ Cannot be assessed
- ◯ Not involved
- ◯ Involved (select all that apply)
  - Site(s)
    - ☐ Myometrium
    - ☐ Endometrium
    - ☐ Cervix

Omentum
- ◯ Not applicable
- ◯ Cannot be assessed
- ◯ Not involved
- ◯ Involved
  - Level of involvement
    - ◯ Macroscopic ◯ Microscopic

Peritoneum (including uterine serosa)
- ◯ Not applicable
- ◯ Cannot be assessed
- ◯ Not involved
- ◯ Involved (select all that apply)
  - Site(s)
    - ☐ Pelvis, *specify site(s)*
    - ☐ Abdomen, *specify site(s)*

Other involved organs(s)/sites(s), *specify*

PERITONEAL CYTOLOGY
- ◯ Not submitted
- ◯ Indeterminate
- ◯ Positive
- ◯ Negative

RESPONSE TO NEOADJUVANT THERAPY
- ◯ Cannot be assessed
- ◯ No prior treatment
- ◯ No definite or minimal response identified (chemotherapy response score (CRS 1))
- ◯ Moderate response identified (CRS 2)
- ◯ Marked response with no or minimal residual cancer (CRS 3)

LYMPH NODE STATUS
- ◯ Cannot be assessed
- ◯ No nodes submitted or found
- ◯ Not involved
- ◯ Involved (select all that apply)
  - ☐ **Regional**
    - ☐ **Left pelvic**
      - Number of nodes examined[a]
      - Number of positive nodes[a]
    - ☐ **Right pelvic**
      - Number of nodes examined[a]
      - Number of positive nodes[a]
    - ☐ **Para-aortic**
      - Number of nodes examined[a]
      - Number of positive nodes[a]
    - **Maximum dimension of largest deposit in regional node** mm
  - ☐ **Non-regional**
    - ☐ **Site 1**
      - Number of nodes examined[a]
      - Number of positive nodes[a]
    - ☐ **Site 2**
      - Number of nodes examined[a]
      - Number of positive nodes[a]

[a] *In some cases it may not be possible to record the actual number of nodes due to fragmentation of the specimen.*

COEXISTENT PATHOLOGY/PRECURSOR LESIONS
- ◯ None identified
- ◯ Present, *specify*

ANCILLARY STUDIES
- ◯ Not performed
- ◯ Performed (select all that apply)
  - ☐ Immunohistochemistry, *specify test(s) and result(s)*
  - ☐ Molecular findings, *specify test(s) and result(s)*
  - ☐ Other, *specify test(s) and result(s)*

Version 2.1 Published September 2021 ISBN: 978-1-922324-25-2

ANCILLARY STUDIES continued

Representative blocks for ancillary studies, *specify those blocks best representing tumour and/or normal tissue for further study*

PROVISIONAL PATHOLOGICAL STAGING

FIGO (2014 edition)[b]

Site of primary tumour

- ◯ Primary tumour, ovary (OV)
- ◯ Primary tumour, fallopian tube (FT)
- ◯ Primary tumour, peritoneum (P)
- ◯ Undesignated: site of primary tumour cannot be assessed (X)

- ◯ I Tumour is confined to ovaries or fallopian tube(s)
  - ◯ IA Tumour limited to 1 ovary (capsule intact) or fallopian tube; no tumour on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings
  - ◯ IB Tumour limited to both ovaries (capsules intact) or fallopian tubes; no tumour on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings
  - ◯ IC Tumour limited to 1 or both ovaries or fallopian tubes,with any of the following:
    - ◯ IC1 Surgical spill
    - ◯ IC2 Capsule ruptured before surgery or tumour on ovarian or fallopian tube surface
    - ◯ IC3 Malignant cells in the ascites or peritoneal washings
- ◯ II Tumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or primary peritoneal cancer
  - ◯ IIA Extension and/or implants on uterus and/or fallopian tubes and/or ovaries
  - ◯ IIB Extension to other pelvic intraperitoneal tissues
- ◯ III Tumour involves 1 or both ovaries or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes
  - ◯ IIIA1 Positive retroperitoneal lymph nodes only (cytologically or histologically proven):
    - ◯ IIIA1(i) Metastasis up to 10 mm in greatest dimension
    - ◯ IIIA1(ii) Metastasis more than 10 mm in greatest dimension
  - ◯ IIIA2 Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes
  - ◯ IIIB Macroscopic peritoneal metastasis beyond the pelvis up to 2 cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes
  - ◯ IIIC Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumour to capsule of liver and spleen without parenchymal involvement of either organ)
- ◯ IV Distant metastasis excluding peritoneal metastases
  - ◯ IVA Pleural effusion with positive cytology
  - ◯ IVB Parenchymal metastases and metastases to extra abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity)

[b] *Reprinted from Int J Gynaecol Obstet., Volume 124, Prat J and FIGO Committee on Gynecologic Oncology, Staging classification for cancer of the ovary, fallopian tube, and peritoneum, pages 1-5, 2014, with permission from Wiley.*

TNM Staging (UICC TNM 8th edition 2016)[c]

TNM Descriptors (only if applicable) (select all that apply)

- ☐ m - multiple primary tumours
- ☐ r - recurrent
- ☐ y - post-therapy

Primary tumour (pT)

- ◯ TX Primary tumour cannot be assessed
- ◯ T0 No evidence of primary tumour
- ◯ T1 Tumour limited to the ovaries (one or both) or fallopian tube(s)
  - ◯ T1a Tumour limited to one ovary (capsule intact) or fallopian tube; capsule intact, no tumour on ovarian surface or fallopian tube surface; no malignant cells in ascites or peritoneal washings
  - ◯ T1b Tumour limited to both ovaries or fallopian tubes; capsule intact, no tumour on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings
  - ◯ T1c Tumour limited to one or both ovaries or fallopian tubes with any of the following:
    - ◯ T1c1 Surgical spill
    - ◯ T1c2 Capsule ruptured before surgery or tumour on ovarian or fallopian tube surface
    - ◯ T1c3 Malignant cells in ascites or peritoneal washings
- ◯ T2 Tumour involves one or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or primary peritoneal cancer
  - ◯ T2a Extension and/or implants on uterus and/or fallopian tube(s) and/or ovary(ies)
  - ◯ T2b Extension to other pelvic tissues, including bowel within the pelvis
- ◯ T3 and/or N1
  Tumour involves one or both ovaries or fallopian tubes or primary peritoneal carcinoma with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes

Regional lymph nodes (pN)

- ◯ N1 Retroperitoneal lymph node metastasis only
  - ◯ N1a Lymph node metastasis not more than 10 mm in greatest dimension
  - ◯ N1b Lymph node metastasis more than 10 mm in greatest dimension
  - ◯ T3a any N
    Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without retroperitoneal lymph node, including bowel involvement
  - ◯ T3b any N
    Macroscopic peritoneal metastasis beyond pelvic brim 2 cm, or less in greatest dimension, including bowel involvement outside the pelvis with or without retroperitoneal nodes
  - ◯ T3c any N
    Peritoneal metastasis beyond pelvic brim more than 2 cm in greatest dimension and/or retroperitoneal lymph node metastasis (includes extension of tumour to capsule of liver and spleen without parenchymal involvement of either organ)

[c] *Reproduced with permission. Source: UICC TNM Classification of Malignant Tumours, 8th Edition, eds by James D. Brierley, Mary K. Gospodarowicz, Christian Wittekind. 2016, Publisher Wiley (incorporating any errata published up until 6th October 2020).*

Version 2.1 Published September 2021 ISBN: 978-1-922324-25-2